GlassScriptPhysician profile
Irene Abramovich
NPI 1407864887
$351,705.92
in general payments reported to CMS, 2019-2025
16 companies · $46K in 2025
The $46K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $14K · 2021: $32K · 2022: $38K · 2023: $70K · 2024: $84K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $109K · Consulting Fee: $39K · Honoraria: $23K · Travel and Lodging: $20K · Food and Beverage: $8,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $109,016.75 |
| Consulting Fee | $38,683.00 |
| Honoraria | $22,850.00 |
| Travel and Lodging | $20,256.09 |
| Food and Beverage | $8,832.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $104,817.96 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $53,257.76 | 2019-2024 | Aristada, Aristada Initio, Lybalvi |
| Supernus Pharmaceuticals, INC. | $51,543.65 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $43,053.78 | 2022-2025 | Uzedy |
| Axsome Therapeutics, INC. | $34,544.91 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $30,433.41 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $21,706.59 | 2019-2021 | |
| Allergan, INC. | $6,418.43 | 2019-2020 | |
| Abbvie INC. | $2,258.10 | 2021-2025 | Vraylar |
| Idorsia Pharmaceuticals US INC | $2,030.00 | 2022-2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $800.00 | 2020 | |
| Lundbeck LLC | $580.88 | 2023-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $166.00 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2021 | |
| Tris Pharma INC | $32.48 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Abramovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.